Skip to main content

Table 1 Characteristics of the PPH trials

From: The early outcomes of candidates with portopulmonary hypertension after liver transplantation

References Institute Sample size Study periods Recipients age MELD score NOS star level
PPH No-PPH PPH No-PPH
DeMartino(2017) [4]
Rajaram(2016) [13]
USA(single center)
USA(single center)
31
13
269
20
2010–2013
2005–2015
57 (50–62)
52(37–62)
32 (25–38)
21.0 ± 9.2
25 (20–29)
24.7 ± 9.5
66
Bozbac(2015) [17]
Salgia (2014) [6]
Mangus(2013) [16]
Turkey(single center)
SRTRa
USA(single center)
47
78
102
156
34,240
1161
2004–2015
2002–2010
2001–2010
42.1 ± 14.1
54 (49–60)
53 (18–76)
N/Ab
14 (11–18)
22(9–40)
N/A
18 (13–25)
18 (6–40)
6
6
7
Yassen(2012) [15] ▲
Pietri(2010) [14]
Saner (2006) [7]
Egypt(single center)
Italy(single center)
Germany(single center)
9
24
23
10
24
48
2008–2011
2003–2008
2004–2005
50.3
54(49–60)
49.6
17 ± 5
25.0 ± 12.0
N/A
14 ± 2
22.0 ± 10.9
N/A
5
6
6
Veloso(2004) [21]
Starkel (2002) [18]
Ramsay(1997) [32]
Taura(1996) [19]
Brazil(single center)
UK(single center)
USA(single center)
Spain(single center)
31
38
103
8
26
107
1103
15
1999–2001
1997–1999
1984–1995
N/A
46
49.2
N/A
45.2
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
6
6
5
5
  1. ▲, random controlled, double-blind study; Jadad score
  2. aSRTR, Scientific Registry of Transplant recipients
  3. bN/A, non-available